Breakeven Date Change • 8h The 10 analysts covering Surgery Partners previously expected the company to break even in 2027. New consensus forecast suggests losses will reduce by 57% to 2026. The company is expected to make a profit of US$7.84m in 2027. Average annual earnings growth of 83% is required to achieve expected profit on schedule.
Breakeven Date Change • May 20
Forecast breakeven date moved forward to 2027 The 11 analysts covering Surgery Partners previously expected the company to break even in 2028. New consensus forecast suggests losses will reduce by 57% to 2026. The company is expected to make a profit of US$10.1m in 2027. Average annual earnings growth of 83% is required to achieve expected profit on schedule. Announcement • May 07
Surgery Partners, Inc. Reaffirms Earnings Guidance for the Full Year 2026 Surgery Partners, Inc. reaffirmed earnings guidance for the full year 2026. For the year, the company's revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion. Announcement • Apr 25
Surgery Partners, Inc., Annual General Meeting, Jun 05, 2026 Surgery Partners, Inc., Annual General Meeting, Jun 05, 2026. Announcement • Apr 18
Surgery Partners, Inc. to Report Q1, 2026 Results on May 05, 2026 Surgery Partners, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 Announcement • Mar 13
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors Surgery Partners, Inc. announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors. Mr. Dean is the former Chief Executive Officer of CommonSpirit Health, one of the largest nonprofit health systems in the United States, with 142 hospitals, over 1,000 care sites, 25,000 physicians, and 150,000 employees across 21 states. From 2019 to 2022, he led the formation and integration of CommonSpirit, advancing clinical quality, operational performance, and community health initiatives at national scale. Prior to CommonSpirit, Mr. Dean served as President and CEO of Dignity Health, where he strengthened patient experience, expanded partnerships, and elevated the organization’s leadership in delivering compassionate, high-quality care. A nationally recognized healthcare leader, Mr. Dean has long championed efforts to reduce health disparities, strengthen the health care workforce, and advance equitable access to care. He has served as an adviser to multiple Presidential Administrations on issues including the Affordable Care Act and COVID-19 vaccination efforts. Mr. Dean has also held several federal and state appointments focused on public health, economic development, and workforce planning. Mr. Dean serves on the boards of McDonald’s Corporation—where he chairs the Board Human Resources & Compensation Committee—Guidehouse, Nox Health, and Progyny, and is a Senior Advisor to Bain Capital. He holds a B.S. in sociology and a master’s degree in educational leadership from Western Michigan University, along with multiple honorary doctorates. Announcement • Feb 25
Surgery Partners, Inc. to Report Q4, 2025 Results on Mar 02, 2026 Surgery Partners, Inc. announced that they will report Q4, 2025 results After-Market on Mar 02, 2026 Announcement • Nov 13
Surgery Partners, Inc. Appoints Justin Oppenheimer as Chief Operating Officer and National Group President, Effective as of January 1, 2026 On November 12, 2025, Surgery Partners, Inc. announced the appointment of Justin Oppenheimer to serve as Chief Operating Officer and National Group President of the Company, effective as of January 1, 2026. Mr. Oppenheimer, age 41, joins Surgery Partners from the Hospital for Special Surgery (HSS), where he spent the past decade in a variety of leadership roles, including Chief Strategy Officer and Chief Operating Officer. He also serves on the Board of Directors for Urban Dove, a New York-based charter school management organization. He holds a B.A. degree in political economy from Princeton University, and an MBA from Harvard Business School. Announcement • Nov 11
Surgery Partners, Inc. Provides Earnings Guidance for the Full Year of 2025 Surgery Partners, Inc. provided earnings guidance for the full year of 2025. For the year, the company expects revenue to be in the range of $3.275 billion to $3.30 billion. Announcement • Oct 29
Duly Health and Care acquired an unknown minority stake in Valley Ambulatory Surgery Center, L.P. from Surgery Partners, Inc. (NasdaqGS:SGRY). Duly Health and Care acquired an unknown minority stake in Valley Ambulatory Surgery Center, L.P. from Surgery Partners, Inc. (NasdaqGS:SGRY) on October 28, 2025.
Duly Health and Care completed the acquisition of an unknown minority stake in Valley Ambulatory Surgery Center, L.P. from Surgery Partners, Inc. (NasdaqGS:SGRY) on October 28, 2025. Announcement • Oct 25
Surgery Partners, Inc. to Report Q3, 2025 Results on Nov 10, 2025 Surgery Partners, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 10, 2025 Announcement • Sep 17
Surgery Partners, Inc. Announces Resignation of Harrison R. Bane, National Group President, Effective October 3, 2025 On September 11, 2025, Harrison R. Bane, National Group President, notified the Board of Directors of Surgery Partners, Inc. (the Company) of his decision to resign from his current role effective October 3, 2025. Mr. Bane’s resignation was not a result of any disagreement between the Company and Mr. Bane on any matter related to the operations, policies, or practices of the Company. Announcement • Aug 09
Surgery Partners, Inc. Announces Board Changes, Effective August 04, 2025 On August 4, 2025, Wayne S. DeVeydt notified the Board of Directors (the Board") of Surgery Partners, Inc. (the Company") of his decision to resign effective immediately as a director and the Executive Chairman of the Board of Directors. Mr. DeVeydt informed the Company that his decision to resign as a member of the Board was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices, and no executive officer of the Company is aware of any such disagreement. Effective as of Mr. DeVeydt's resignation, the Board appointed Blair E. Hendrix to serve as Chairman of the Board of Directors. Pursuant to the authority of the Board under the Company's Amended and Restated Certificate of Incorporation to establish the number of directors on the Board from time to time, the Board reduced the size of the Board from 11 directors to 10 directors effective August 4, 2025. Announcement • Aug 05
Surgery Partners, Inc. Reaffirms Earnings Guidance for the Full Year 2025 Surgery Partners, Inc. reaffirmed earnings guidance for the full year 2025. For the period, company expects revenue to be in the range of $3.30 billion to $3.45 billion. Announcement • Jul 18
Surgery Partners, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Surgery Partners, Inc. announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2025 Announcement • Jun 18
Surgery Partners, Inc. Provides Revenue Guidance for 2025 SURGERY PARTNERS, INC. provided revenue guidance for 2025. For the period, the company expected revenue to be in the range of $3.30 billion to $3.45 billion. Announcement • Jun 17
Bain Capital Private Equity, LP cancelled the acquisition of remaining 60.7% stake in Surgery Partners, Inc. (NasdaqGS:SGRY). Bain Capital Private Equity, LP made a non-binding proposal to acquire remaining 60.7% stake in Surgery Partners, Inc. (NasdaqGS:SGRY) for $2 billion on January 27, 2025. Bain Capital will pay cash consideration of $25.75 per share. The Proposal is subject to the completion of confirmatory due diligence and the negotiation and execution of mutually acceptable definitive transaction documentation. A Special Committee of independent directors of the Board of Surgery Partners will consider the Bain Capital Proposal.
Kirkland & Ellis LLP acted as legal counsel for Bain. Viper Partners acted as financial advisor to Bain.
Bain Capital Private Equity, LP cancelled the acquisition of remaining 60.7% stake in Surgery Partners, Inc. (NasdaqGS:SGRY) on June 17, 2025. The Independent Committee, after considering the Proposal and with the assistance of independent financial and legal advisors, ultimately determined that Surgery Partners’ prospects to deliver long-term growth and value creation as an independent publicly traded company exceeded the value of the Proposal. The Independent Committee’s conclusion demonstrates its ongoing confidence in the Company’s ability to continue implementing its established long-term growth algorithm and disciplined business execution to enhance shareholder value. Announcement • May 12
Surgery Partners, Inc. Reaffirms Earnings Guidance for the Year 2025 Surgery Partners, Inc. reaffirms earnings guidance for the year 2025. Full year 2025 revenue guidance reaffirmed to be in the range of $3.30 billion to $3.45 billion. Announcement • Apr 26
Surgery Partners, Inc., Annual General Meeting, Jun 06, 2025 Surgery Partners, Inc., Annual General Meeting, Jun 06, 2025. Location: eee.meetnow.global/myrk52a, United States Announcement • Apr 19
Surgery Partners, Inc. to Report Q1, 2025 Results on May 12, 2025 Surgery Partners, Inc. announced that they will report Q1, 2025 results on May 12, 2025 Announcement • Mar 06
Surgery Partners, Inc. announced delayed annual 10-K filing On 03/04/2025, Surgery Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Mar 03
Surgery Partners, Inc. Provides Earnings Guidance for the Year 2025 Surgery Partners, Inc. provided earnings guidance for the year 2025. Full year 2025 revenue expected to be in the range of $3.30 billion to $3.45 billion. Announcement • Feb 18
Surgery Partners, Inc. to Report Q4, 2024 Results on Mar 03, 2025 Surgery Partners, Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 03, 2025 Announcement • Jan 29
Bain Capital Private Equity, LP made a non-binding proposal to acquire remaining 60.7% stake in Surgery Partners, Inc. (NasdaqGS:SGRY) for $2 billion. Bain Capital Private Equity, LP made a non-binding proposal to acquire remaining 60.7% stake in Surgery Partners, Inc. (NasdaqGS:SGRY) for $2 billion on January 27, 2025. Bain Capital will pay cash consideration of $25.75 per share. The Proposal is subject to the completion of confirmatory due diligence and the negotiation and execution of mutually acceptable definitive transaction documentation. A Special Committee of independent directors of the Board of Surgery Partners will consider the Bain Capital Proposal.
Kirkland & Ellis LLP acted as legal counsel for Bain. Announcement • Jan 14
Surgery Partners, Inc. Names Laura L. Forese to Board of Directors Surgery Partners, Inc. announced that Dr. Laura L. Forese has been appointed to serve as an independent director on its Board of Directors. Dr. Forese’s appointment, which is effective January 10, 2025, will increase the size of Surgery Partners’ Board to eleven members. Dr. Forese joins the Surgery Partners Board with extensive healthcare experience. Her career in healthcare administration spans over 40 years, most recently serving as an executive vice president and chief operating officer for New York-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems, including 10 hospital campuses, approximately 200 primary and specialty care clinics and medical groups, and more than 45,000 employees and affiliated physicians. Prior to that, Dr. Forese held other executive and management positions in the New York-Presbyterian organization with a focus on patient safety, efficiency, and transformation. Under Dr. Forese's leadership, the New York-Presbyterian Medical Groups was established to expand the organization's regional footprint and standardize financial, operational, and clinical practices to ensure that patients received the same exceptional standard of care throughout the healthcare system. Active in multiple healthcare and civic organizations, Dr. Forese is chair emerita of the NIH Clinical Research Hospital board and trustee emerita of Princeton University. Currently, she serves as a board director of the Shubert Organization, a trustee of the Mother Cabrini Health Foundation, and director of Nereid Therapeutics and Veuu Inc. From 2015 to 2021, Dr. Forese was a director of Cantel Medical Corp. until it was acquired by another public healthcare company. Dr. Forese is an orthopedic surgeon. She obtained her medical degree from Columbia University College of Physicians & Surgeons and a masters degree in health services management from the Columbia University School of Public Health. Dr. Forese received a bachelor’s degree in civil engineering and operations research from Princeton University, where she graduated summa cum laude and Phi Beta Kappa. Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.039 loss in 3Q 2023) Third quarter 2024 results: US$0.25 loss per share (further deteriorated from US$0.039 loss in 3Q 2023). Revenue: US$770.4m (up 14% from 3Q 2023). Net loss: US$31.7m (loss widened US$26.8m from 3Q 2023). Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 13 The 13 analysts covering Surgery Partners previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$52.6m in 2024. Earnings growth of 1.7% is required to achieve expected profit on schedule.
Announcement • Oct 21
Surgery Partners, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Surgery Partners, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024 Buy Or Sell Opportunity • Aug 23
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to €25.80. The fair value is estimated to be €21.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 77%. Reported Earnings • Aug 07
Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.15 profit in 2Q 2023) Second quarter 2024 results: US$0.12 loss per share (down from US$0.15 profit in 2Q 2023). Revenue: US$762.1m (up 14% from 2Q 2023). Net loss: US$15.5m (down 182% from profit in 2Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Aug 07
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 8.7% to €27.40. The fair value is estimated to be €22.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 47% per annum over the same time period. Announcement • Aug 06
Surgery Partners, Inc. Updates Earnings Guidance for the Year 2024 Surgery Partners, Inc. updated earnings guidance for the year 2024. The Company raised its outlook for 2024 revenues to be greater than $3.075 billion. Announcement • Jul 17
Surgery Partners, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Surgery Partners, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 06, 2024 Announcement • May 08
Surgery Partners, Inc. Raises Earnings Guidance for the Year 2024 Surgery Partners, Inc. raised earnings guidance for the year 2024. The Company raised its outlook for 2024 revenues to be at least $3.05 billion. New Risk • May 07
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (€1.4m sold). Announcement • Apr 28
Surgery Partners, Inc., Annual General Meeting, Jun 06, 2024 Surgery Partners, Inc., Annual General Meeting, Jun 06, 2024, at 14:00 Central Standard Time. Agenda: To elect the four Class III director nominees named in this Proxy Statement to the Board of Directors of Surgery Partners, Inc. (the "Company") for a term of three years; to approve, on an advisory basis, the compensation paid by the Company to its named executive officers; to approve the Surgery Partners, Inc. Employee Stock Purchase Plan (the "ESPP"); to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider and act upon any other business that may properly come before the 2024 annual meeting of stockholders and at any adjournment or postponement thereof. Announcement • Apr 19
Surgery Partners, Inc. to Report Q1, 2024 Results on May 07, 2024 Surgery Partners, Inc. announced that they will report Q1, 2024 results Pre-Market on May 07, 2024 Announcement • Feb 27
Surgery Partners, Inc. Provides Earnings Guidance for the Year 2024 Surgery Partners, Inc. provided earnings guidance for the year 2024. For the year, the company projects 2024 revenues to be greater than $3.0 billion. Announcement • Feb 09
Surgery Partners, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Surgery Partners, Inc. announced that they will report Q4, 2023 results on Feb 26, 2024 Announcement • Jan 08
Surgery Partners, Inc. Reaffirms Earnings Guidance for the Year 2023 Surgery Partners, Inc. reaffirms earnings guidance for the year 2024. The Company is re-affirming its 2023 Revenue guidance of approximately $2.75 billion. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2024 The 10 analysts covering Surgery Partners previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$103.2m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 22
Executive Chairman recently sold €2.1m worth of stock On the 19th of December, Wayne DeVeydt sold around 68k shares on-market at roughly €30.46 per share. This transaction amounted to 34% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Wayne's only on-market trade for the last 12 months. Announcement • Dec 15
Surgery Partners, Inc. has filed a Follow-on Equity Offering. Surgery Partners, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 8,000,000 Announcement • Nov 08
Surgery Partners, Inc. Provides Earnings Guidance for the Full Year 2023 Surgery Partners, Inc. provided earnings guidance for the full year 2023. For the period, the company expects revenue of approximately $2.75 billion. Reported Earnings • Nov 08
Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.28 loss in 3Q 2022) Third quarter 2023 results: US$0.039 loss per share (improved from US$0.28 loss in 3Q 2022). Revenue: US$674.1m (up 8.6% from 3Q 2022). Net loss: US$4.90m (loss narrowed 80% from 3Q 2022). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 1.3% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Nov 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (42% increase in shares outstanding). Announcement • Oct 07
Surgery Partners, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Surgery Partners, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023 Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$0.15 (vs US$0.21 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0.15 (up from US$0.21 loss in 2Q 2022). Revenue: US$667.6m (up 8.5% from 2Q 2022). Net income: US$18.9m (up US$37.3m from 2Q 2022). Profit margin: 2.8% (up from net loss in 2Q 2022). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Jul 22
Surgery Partners, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Surgery Partners, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 01, 2023 Recent Insider Transactions • May 19
President of National Group recently sold €241k worth of stock On the 17th of May, Bradley Owens sold around 7k shares on-market at roughly €33.54 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €663k. Insiders have been net sellers, collectively disposing of €4.5m more than they bought in the last 12 months. Reported Earnings • May 03
First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 profit in 1Q 2022) First quarter 2023 results: US$0.20 loss per share (down from US$0.14 profit in 1Q 2022). Revenue: US$666.2m (up 12% from 1Q 2022). Net loss: US$24.9m (down 304% from profit in 1Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 05
CEO & Director recently sold €242k worth of stock On the 31st of March, J. Evans sold around 8k shares on-market at roughly €31.53 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €663k. J. has been a net seller over the last 12 months, reducing personal holdings by €1.7m. Recent Insider Transactions • Mar 16
CEO & Director recently sold €663k worth of stock On the 15th of March, J. Evans sold around 23k shares on-market at roughly €29.09 per share. This transaction amounted to 5.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. J. has been a net seller over the last 12 months, reducing personal holdings by €2.1m. Recent Insider Transactions • Mar 02
CEO & Director recently sold €634k worth of stock On the 27th of February, J. Evans sold around 20k shares on-market at roughly €31.65 per share. This transaction amounted to 5.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. J. has been a net seller over the last 12 months, reducing personal holdings by €2.3m. Reported Earnings • Mar 02
Full year 2022 earnings released: US$0.59 loss per share (vs US$1.12 loss in FY 2021) Full year 2022 results: US$0.59 loss per share (improved from US$1.12 loss in FY 2021). Revenue: US$2.54b (up 14% from FY 2021). Net loss: US$54.6m (loss narrowed 33% from FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Feb 16
CEO & Director recently sold €186k worth of stock On the 13th of February, J. Evans sold around 6k shares on-market at roughly €31.63 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. J. has been a net seller over the last 12 months, reducing personal holdings by €2.3m. Announcement • Feb 10
Surgery Partners, Inc. to Report Q4, 2022 Results on Mar 01, 2023 Surgery Partners, Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Mar 01, 2023 Recent Insider Transactions • Feb 07
Executive VP & CFO recently sold €64k worth of stock On the 2nd of February, David Doherty sold around 2k shares on-market at roughly €32.83 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €99k. David has been a net seller over the last 12 months, reducing personal holdings by €402k. Announcement • Jan 10
Surgery Partners, Inc. Reaffirms Revenue Guidance for 2022 Surgery Partners, Inc. reaffirmed revenue guidance for 2022. For the period, the company expects revenue guidance of $2.50 billion to $2.55 billion. Announcement • Dec 24
Surgery Partners, Inc. announced that it has received $224.999989 million in funding from Bain Capital Private Equity, LP On December 22, 2022, Surgery Partners, Inc. closed the transaction. Recent Insider Transactions • Nov 23
Independent Director recently bought €478k worth of stock On the 21st of November, Teresa DeLuca bought around 20k shares on-market at roughly €23.91 per share. This transaction amounted to 72% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €7.0m more in shares than they bought in the last 12 months. Announcement • Nov 23
Surgery Partners, Inc. has completed a Follow-on Equity Offering in the amount of $575.000006 million. Surgery Partners, Inc. has completed a Follow-on Equity Offering in the amount of $575.000006 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 23,469,388
Price\Range: $24.5
Discount Per Security: $0.8575 Announcement • Nov 22
Surgery Partners, Inc. announced that it expects to receive $225 million in funding from BCPE Seminole Holdings LP Surgery Partners, Inc. announced a private placement of common stock for gross proceeds of $225,000,000 on November 21, 2022. The transaction will include participation from existing investor, BCPE Seminole Holdings LP, an affiliate of Bain Capital. The security will be issued at the same public offering price per share. The transaction is expected to close within 30 days of the date of the underwritten public offering, subject to the satisfaction of customary closing conditions. Recent Insider Transactions • Nov 16
Insider recently sold €99k worth of stock On the 9th of November, Laura Brocklehurst sold around 4k shares on-market at roughly €22.85 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €7.7m more than they bought in the last 12 months. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Pat Maryland was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 3Q 2021) Third quarter 2022 results: US$0.28 loss per share. Revenue: US$620.6m (up 11% from 3Q 2021). Net loss: US$25.0m (loss widened 9.2% from 3Q 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Announcement • Nov 09
Surgery Partners, Inc. reaffirms Earnings Guidance for the Fiscal 2022 Surgery Partners, Inc. reaffirmed earnings guidance for the fiscal 2022. For the period, the company estimates revenue in the range of $2.5 billion to $2.55 billion. Announcement • Oct 11
Surgery Partners, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Surgery Partners, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 08, 2022 Reported Earnings • Aug 03
Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.39 loss in 2Q 2021) Second quarter 2022 results: US$0.21 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$615.4m (up 13% from 2Q 2021). Net loss: US$18.4m (loss narrowed 32% from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 3.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 82% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 03
Surgery Partners, Inc. Provides Revenue Guidance for the Year 2022 Surgery Partners, Inc. provided revenue guidance for the year 2022. For the year, the company expects revenue in the range of $2.5 billion to $2.6 billion. Announcement • Jun 30
Surgery Partners, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Surgery Partners, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 02, 2022 Recent Insider Transactions • Jun 09
President of ASC Group recently sold €471k worth of stock On the 6th of June, George Goodwin sold around 13k shares on-market at roughly €37.40 per share. In the last 3 months, there was an even bigger sale from another insider worth €697k. Insiders have been net sellers, collectively disposing of €7.6m more than they bought in the last 12 months. Recent Insider Transactions • May 26
President of ASC Group recently sold €509k worth of stock On the 23rd of May, George Goodwin sold around 14k shares on-market at roughly €37.46 per share. In the last 3 months, there was an even bigger sale from another insider worth €697k. Insiders have been net sellers, collectively disposing of €7.5m more than they bought in the last 12 months. Reported Earnings • May 04
First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.57 loss in 1Q 2021) First quarter 2022 results: EPS: US$0.14 (up from US$0.57 loss in 1Q 2021). Revenue: US$596.2m (up 16% from 1Q 2021). Net income: US$12.2m (up US$43.5m from 1Q 2021). Profit margin: 2.0% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 12%, compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 04
Surgery Partners, Inc. Raises Earnings Guidance for the Year 2022 Surgery Partners, Inc. raised earnings guidance for the year 2022. For the year, the company raised its guidance of revenue to $2.5 billion to $2.6 billion. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Pat Maryland was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 09
Surgery Partners, Inc., Annual General Meeting, May 19, 2022 Surgery Partners, Inc., Annual General Meeting, May 19, 2022, at 08:00 Central Standard Time. Location: 310 Seven Springs Way, Suite 500 Brentwood Tennessee United States Agenda: To elect the three Class I director nominees to the Board of Directors of Surgery Partners, Inc. for a term of three years; to approve, on an advisory basis, the compensation paid by the Company to its named executive officers; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; and to consider and act upon any other business that may properly come before the 2022 annual meeting of stockholders and at any adjournment or postponement thereof. Announcement • Apr 08
Surgery Partners, Inc. to Report Q1, 2022 Results on May 03, 2022 Surgery Partners, Inc. announced that they will report Q1, 2022 results Pre-Market on May 03, 2022 Recent Insider Transactions • Apr 05
CEO & Director recently sold €571k worth of stock On the 1st of April, J. Evans sold around 11k shares on-market at roughly €49.79 per share. In the last 3 months, there was an even bigger sale from another insider worth €697k. J. has been a seller over the last 12 months, reducing personal holdings by €2.1m. Recent Insider Transactions • Mar 15
CEO & Director recently sold €253k worth of stock On the 11th of March, J. Evans sold around 5k shares on-market at roughly €49.93 per share. In the last 3 months, they made an even bigger sale worth €655k. J. has been a seller over the last 12 months, reducing personal holdings by €907k. Recent Insider Transactions • Mar 09
CEO & Director recently sold €655k worth of stock On the 28th of February, J. Evans sold around 14k shares on-market at roughly €46.53 per share. This was the largest sale by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months. Reported Earnings • Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.98 loss per share (up from US$3.19 loss in FY 2020). Revenue: US$2.23b (up 20% from FY 2020). Net loss: US$70.9m (loss narrowed 54% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 02
Surgery Partners, Inc. Provides Earnings Guidance for the Year 2022 Surgery Partners, Inc. provided earnings Guidance for the year 2022. The Company projects that it will be able to grow 2022 revenues to at least $2.5 billion, representing at least 12% growth over 2021 results. Announcement • Feb 05
Surgery Partners, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Surgery Partners, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022 Announcement • Jan 12
Surgery Partners, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ended December 31, 2021 Surgery Partners, Inc. reaffirmed earnings guidance for the fiscal year ended December 31, 2021. For the period, the company expects revenue of 19% to 21% growth over 2020 results. Reported Earnings • Nov 04
Third quarter 2021 earnings released: US$0.28 loss per share (vs US$1.47 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$559.2m (up 13% from 3Q 2020). Net loss: US$22.9m (loss narrowed 68% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 7 analysts covering Surgery Partners expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$43.7m in 2022. Average annual earnings growth of 106% is required to achieve expected profit on schedule. Recent Insider Transactions • Aug 13
Independent Director recently bought €80k worth of stock On the 10th of August, Teresa DeLuca bought around 2k shares on-market at roughly €39.83 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €7.8m more in shares than they bought in the last 12 months. Announcement • Aug 06
Surgery Partners, Inc. Provides Earnings Guidance for the Full Year 2021 Surgery Partners, Inc. provided earnings guidance for the full year 2021. For the year, the company continued to project that it will be able to grow 2021 revenues by 18% to 20% over 2020 results. Reported Earnings • Aug 05
Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.86 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$543.3m (up 45% from 2Q 2020). Net loss: US$26.9m (loss narrowed 36% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 10
Independent Director recently sold €136k worth of stock On the 8th of June, Teresa DeLuca sold around 3k shares on-market at roughly €51.77 per share. In the last 3 months, there was an even bigger sale from another insider worth €2.6m. Insiders have been net sellers, collectively disposing of €7.9m more than they bought in the last 12 months. 
